

## MEDICAL PRIOR AUTHORIZATION

### Eloxatin (oxaliplatin) oxaliplatin (generic)

#### POLICY

##### A. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

Oxaliplatin, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for:

1. Adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor
2. Treatment of advanced colorectal cancer

##### Compendial Uses

1. Bladder cancer
2. Colorectal cancer
3. Esophagus or esophagogastric junction cancers
4. Gastric cancer
5. Hepatobiliary cancers
  - Extrahepatic cholangiocarcinoma
  - Intrahepatic cholangiocarcinoma
  - Gallbladder cancer
6. Neuroendocrine tumors of the pancreas
7. Non-Hodgkin's lymphoma
  - Adult T-cell leukemia/lymphoma
  - AIDS-related B-cell lymphoma
  - Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
  - Diffuse large B-cell lymphoma
  - Extranodal NK/T-cell lymphoma, nasal type
  - Follicular lymphoma
  - Gastric MALT lymphoma
  - Mantle cell lymphoma
  - Mycosis fungoides/Sézary syndrome
  - Nongastric MALT lymphoma
  - Peripheral T-cell lymphoma
  - Primary cutaneous B-cell lymphoma
  - Primary cutaneous CD30+ T-cell lymphoproliferative disorders
  - Splenic marginal zone lymphoma
8. Occult primary cancer
9. Ovarian cancer (epithelial), fallopian tube cancer, and primary peritoneal cancer
10. Pancreatic adenocarcinoma
11. Testicular cancer

All other indications are considered experimental/investigational and are not a covered benefit.

## **B. CRITERIA FOR INITIAL APPROVAL**

### **1. Colon and Rectal Cancer**

Authorization of 12 months may be granted for the treatment of colon and rectal cancers.

### **2. Pancreatic Adenocarcinoma**

Authorization of 12 months may be granted for the treatment of pancreatic adenocarcinoma.

### **3. Esophageal and Esophagogastric Junction Cancers**

Authorization of 12 months may be granted for the treatment of esophageal and esophagogastric junction cancers.

### **4. Gastric Cancer**

Authorization of 12 months may be granted for the treatment of gastric cancer.

### **5. Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Cancer**

Authorization of 12 months may be granted for the treatment of intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer.

### **6. Neuroendocrine Tumors of the Pancreas**

Authorization of 12 months may be granted for the treatment of neuroendocrine tumors of the pancreas.

### **7. Non-Hodgkin's Lymphoma (NHL)**

Authorization of 12 months may be granted for the treatment of NHL.

### **8. Occult Primary Tumors (cancer of unknown primary)**

Authorization for 12 months may be granted for the treatment of occult primary tumors.

### **9. Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer**

Authorization of 12 months may be granted for the treatment of epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

### **10. Testicular Cancer**

Authorization of 12 months may be granted for the treatment of testicular cancer.

### **11. Bladder Cancer**

Authorization of 12 months may be granted for the treatment of bladder cancer with non-urothelial cell histology.

## **C. CONTINUATION OF THERAPY**

All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria.

## **D. REFERENCES**

1. Eloxatin [package insert]. Bridgewater, NJ: Sanofi-aventis U.S. LLC; October 2015.
2. Oxaliplatin [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; January 2016.
3. The NCCN Drugs & Biologics Compendium™. © 2015 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed August 3, 2016.
4. DRUGDEX® System (electronic version). Truven Health Analytics, Ann Arbor, MI. Available at <http://www.micromedexsolutions.com> [available with subscription]. Accessed August 18, 2016.